Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

References

• National Multiple Sclerosis Society. About MS. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/index.aspx [Last accessed: 2009 June 8]
   Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• The PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003;9:585-91
   PubMed Web of Science ®Google Scholar
• Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 2002;8:2-9
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Freedman MS. Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence. Neurol Sci 2008;29(Suppl 2):S250-2
   Google Scholar
• Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007;20:269-74
   PubMed Web of Science ®Google Scholar
• Bashir K, Buchwald L, Coyle P, et al. MS patient management: optimizing immunomodulatory therapy for MS patients. Int J MS Care 2002;(Jun Suppl):1–7
   Google Scholar
• Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology 2004;63:S33-40
   PubMed Web of Science ®Google Scholar
• Freedman MS, Paty DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157-68
   PubMed Web of Science ®Google Scholar
• International Working Group for Treatment Optimization in MS. Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2004;11:43-7
   PubMed Web of Science ®Google Scholar
• Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon {beta}-1a: analysis of the PRISMS study. Mult Scler 2008;14:1234-41
   PubMed Web of Science ®Google Scholar
• Ruiz-Pena JL, Duque P, Izquierdo G. Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria. BMC Neurol 2008;8:3
   PubMedGoogle Scholar
• Karussis D, Biermann LD, Bohlega S, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006;13:61-71
   PubMed Web of Science ®Google Scholar
• Stuart WH. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. J Manag Care Pharm 2004;10(3 Suppl S-b):S19-25
   PubMedGoogle Scholar
• Rich SR, Coleman IC, Cook R, et al. Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm 2004;10(3 Suppl S-b):S26-32
   PubMedGoogle Scholar
• Rieckmann P, Toyka KV, Bassetti C, et al. Escalating immunotherapy of multiple sclerosis – new aspects and practical application. J Neurol 2004;251:1329-39
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 2003;60:1849-51
   PubMed Web of Science ®Google Scholar
• Ytterberg C, Johansson S, Andersson M, et al. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Acta Neurol Scand 2007;116:96-9
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006;63:1388-93
   PubMed Web of Science ®Google Scholar
• Caon C, Din M, Ching W, et al. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006;13:471-4
   PubMed Web of Science ®Google Scholar
• Carrá A, Onaha P, Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008;15:386-93
   PubMed Web of Science ®Google Scholar
• Pulicken M, Bash CN, Costello K, et al. Optimization of the safety and efficacy of interferon beta-1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 2005;11:169-74
   PubMed Web of Science ®Google Scholar
• Téllez N, Río J, Tintoré M, et al. Mitoxantrone in MS patients, non-responders to interferon. 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis 2005 September 28–October 1, Madrid, Spain
   Google Scholar
• Lus G, Romano F, Scuotto A, et al. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 2004;51:15-20
   PubMed Web of Science ®Google Scholar
• Reggio E, Nicoletti A, Fiorilla T, et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients – twenty-four months follow-up. J Neurol 2005;252:1255-61
   PubMed Web of Science ®Google Scholar
• Correale J, Rush C, Amengual A, et al. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. J Neuroimmunol 2005;162:173-83
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004;101:8705-8
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002;58:314-17
   PubMed Web of Science ®Google Scholar
• Minagar A, Alexander JS, Schwendimann RN et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008;65:199-204
   PubMed Web of Science ®Google Scholar
• Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-9
   PubMed Web of Science ®Google Scholar
• Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-82
   PubMed Web of Science ®Google Scholar
• Cohen JA, Calabresi PA, Chakraborty S, et al. Avonex Combination Trial in relapsing-remitting MS: rationale, design and baseline data. Mult Scler 2008;14:370-82
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• Durelli L, Barbero P, Bergui M, et al. The OPTimization of Interferon for MS Study: 375 mug interferon beta-1b in suboptimal responders. J Neurol 2008;255:1315-23
   PubMed Web of Science ®Google Scholar
• The PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Bacchetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009;15:50-8
   PubMed Web of Science ®Google Scholar
• Tysabri® (natalizumab). Full Prescribing Information, Biogen Idec Inc., Cambridge, MA, 2008
   Google Scholar
• TYSABRI® (natalizumab) Information Center, 2009. Available at: http://www.biogenidec.com/site/tysabri-information-center.html [Last accessed: 2009 March 31]
   Google Scholar
• Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009;72:535-41
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-6
   PubMed Web of Science ®Google Scholar
• Zaffaroni M. Treatment optimisation in multiple sclerosis. Neurol Sci 2005;26(Suppl 4):S187-92
   PubMedGoogle Scholar
• O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007;13:336-42
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-52
   PubMed Web of Science ®Google Scholar
• Tsai KY, Tsai CP, Liao N. Sjögren's syndrome with central nervous system involvement presenting as multiple sclerosis with failure response to beta-interferon. Eur Neurol 2001;45:59-60
   PubMed Web of Science ®Google Scholar
• Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;356:2603-13
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-16
   PubMed Web of Science ®Google Scholar
• Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006;253:287-93
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cutter G, Tyry T, et al. Does multiple sclerosis-associated disability differ between races?. Neurology 2006;66:1235-40
   PubMed Web of Science ®Google Scholar
• Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler 2006;12:775-81
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003;9:293-8
   PubMed Web of Science ®Google Scholar
• Kaufman MD, Johnson SK, Moyer D, et al. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil 2003;82:582-90
   PubMed Web of Science ®Google Scholar
• Cree BA, AL-Sabbagh A, Bennett R, et al. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol 2005;62:1681-3
   PubMed Web of Science ®Google Scholar
• Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004;63:2039-45
   PubMed Web of Science ®Google Scholar
• Reder A. Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes. Mult Scler 2007;13(Suppl 1):S53-62
   Google Scholar
• Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-84
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-27
   PubMed Web of Science ®Google Scholar
• Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998;51:1698-702
   PubMed Web of Science ®Google Scholar
• Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72:705-11
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17
   PubMed Web of Science ®Google Scholar
• Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55
   PubMed Web of Science ®Google Scholar
• Woo DA, Olek MJ, Frohman EM. Diagnosis and management of multiple sclerosis: case studies. Neurol Clin 2006;24:199-214
   PubMed Web of Science ®Google Scholar
• Novantrone® (mitoxantrone for injection concentrate). Full Prescribing Information, EMD Serono, Inc., Rockland, MA, 2006
   Google Scholar
• Debouverie M, Taillandier L, Pittion-Vouyovitch S, et al. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment. Mult Scler 2007;13:626-31
   PubMed Web of Science ®Google Scholar
• Ramtahal J, Jacob A, Das K, et al. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006;253:1160-4
   PubMed Web of Science ®Google Scholar
• Rebif® (interferon beta-1a). Full Prescribing Information, EMD Serono, Inc., and Pfizer Inc, Rockland, MA, and New York, NY, 2008
   Google Scholar
• Avonex® (interferon beta-1a IM for injection). Full Prescribing Information, Biogen Idec Inc, Cambridge, MA, 2006
   Google Scholar
• Betaseron® (interferon beta-1b SC for injection). Full Prescribing Information, Bayer HealthCare Pharmaceuticals, Wayne, NJ, 2007
   Google Scholar
• Martinelli Boneschi F, Rovaris M, Comi G, et al. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Mult Scler 2004;10:341-7
   PubMed Web of Science ®Google Scholar
• Traboulsee A, the CMSC Working Group. Vancouver Consortium of MS Centers Guidelines for a standardized MRI protocol for MS: Update and Implementation, 2004. Available at: http://www.mscare.org/cmsc/Vancouver-2003-Guidelines-for-a-standardized-MRI-protocol-for-MS.html [Last accessed: 2008 September 24]
   Google Scholar
• Agosta F, Rovaris M, Pagani E, et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006;129:2620-7
   PubMed Web of Science ®Google Scholar
• Jeffery DR, Chepuri N, Durden D, et al. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 2005;11:296-301
   PubMed Web of Science ®Google Scholar